Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Leerink Partnrs issued their Q4 2026 earnings per share estimates for shares of Larimar Therapeutics in a note issued to investors on Thursday, August 14th. Leerink Partnrs analyst J. Park anticipates that the company will earn ($0.59) per share for the quarter. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share.
LRMR has been the topic of a number of other research reports. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. JMP Securities reduced their target price on Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating on the stock in a research note on Friday, August 15th. Wedbush reduced their target price on Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 24th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. One research analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $18.43.
Get Our Latest Analysis on LRMR
Larimar Therapeutics Stock Performance
LRMR stock traded up $0.22 on Monday, reaching $3.91. The company had a trading volume of 1,421,476 shares, compared to its average volume of 1,828,442. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $9.50. The company's fifty day moving average is $3.38 and its 200 day moving average is $2.78. The company has a market cap of $323.67 million, a P/E ratio of -2.51 and a beta of 0.93.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.06.
Institutional Trading of Larimar Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC increased its holdings in shares of Larimar Therapeutics by 15.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company's stock worth $24,936,000 after buying an additional 876,431 shares during the last quarter. Blue Owl Capital Holdings LP increased its holdings in shares of Larimar Therapeutics by 11.7% during the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company's stock worth $18,007,000 after buying an additional 486,211 shares during the last quarter. Opaleye Management Inc. increased its holdings in shares of Larimar Therapeutics by 114.7% during the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company's stock worth $11,878,000 after buying an additional 2,195,923 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company's stock worth $8,127,000 after buying an additional 399,123 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its holdings in Larimar Therapeutics by 46.6% in the 1st quarter. Alyeska Investment Group L.P. now owns 1,442,473 shares of the company's stock valued at $3,101,000 after purchasing an additional 458,396 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Larimar Therapeutics
In other Larimar Therapeutics news, Director James E. Flynn purchased 9,375,000 shares of Larimar Therapeutics stock in a transaction on Thursday, July 31st. The shares were bought at an average price of $3.20 per share, with a total value of $30,000,000.00. Following the purchase, the director directly owned 9,538,945 shares in the company, valued at $30,524,624. This trade represents a 5,718.38% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.50% of the stock is currently owned by corporate insiders.
About Larimar Therapeutics
(
Get Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
See Also
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
